About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
All
2024
2023
2022
2021
2020
2019
03
Sep
2024
11:05 E.S.T.
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Read more
26
Aug
2024
10:35 E.S.T.
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Read more
07
Aug
2024
02:00 E.S.T.
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Read more
06
Aug
2024
16:30 E.S.T.
Cellectis Provides Financial Results for the Second Quarter 2024
Read more
01
Aug
2024
16:30 E.S.T.
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
Read more
25
Jul
2024
16:30 E.S.T.
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Read more
28
Jun
2024
11:04 E.S.T.
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
Read more
20
Jun
2024
16:30 E.S.T.
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
Read more
12
Jun
2024
10:27 E.S.T.
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Read more
04
Jun
2024
11:30 E.S.T.
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
Read more
1
2
Next